Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma

European Journal of Endocrinology

Volumn 166, Issue 6, 2012, Pages 1049-1060

  Dinets, Andrii ^a,b   Hulchiy, Mykola ^b   Sofiadis, Anastasios ^a   Ghaderi, Mehran ^c   Höög, Anders ^a,c   Larsson, Catharina ^a   Zedenius, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Kyiv City Teaching Endocrinological Center   (Ukraine)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; PROTEIN BCL 2;

ADULT; ARTICLE; BRAF GENE; CANCER PATIENT; CCND1 GENE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC ASSOCIATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NUCLEAR ACCIDENT; ONCOGENE; PRIORITY JOURNAL; PTC1 GENE; PTC3 GENE; PYROSEQUENCING; RADIATION EXPOSURE; REAL TIME POLYMERASE CHAIN REACTION; RET GENE; SEX DIFFERENCE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME; UKRAINE;

ADULT; AGED; CARCINOMA, PAPILLARY; CHERNOBYL NUCLEAR ACCIDENT; COHORT STUDIES; CYCLIN A; CYCLIN D1; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, RADIATION-INDUCED; NUCLEAR RECEPTOR COACTIVATORS; PHENOTYPE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-RET; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UKRAINE; UP-REGULATION; USSR;

EID: 84862746887     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0144     Document Type: Article

References (56)

1. Sipos JA & Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clinical Oncology 2010 22 395-404. (doi:10.1016/j.clon.2010.05.004)
2. Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, Likhtarev IA, Fink DJ, Markov VV, Greenebaum E, Olijnyk VA, Masnyk IJ, Shpak VM, McConnell RJ, Tereshchenko VP, Robbins J, Zvinchuk OV, Zablotska LB, Hatch M, Luckyanov NK, Ron E, Thomas TL, Voilleque PG & Beebe GW. A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. Journal of the National Cancer Institute 2006 98 897-903. (doi:10.1093/jnci/djj244)
3. Avetisian IL, Gulchiy NV, Demidiuk AP & Stashuk AV. Thyroid pathology in residents of the Kiev region, Ukraine, during preand post-Chernobyl periods. Journal of Environmental Pathology, Toxicology and Oncology 1996 15 233-237.
4. Trovisco V, Soares P, Preto A, Castro P, Maximo V & Sobrinho-Simoes M. Molecular genetics of papillary thyroid carcinoma: great expectations. Arquivos Brasileiros de Endocrinologia e Metabologia 2007 51 643-653. (doi:10.1590/S0004-27302007000500002)
5. Likhtarov I, Kovgan L, Vavilov S, Chepurny M, Ron E, Lubin J, Bouville A, Tronko N, Bogdanova T, Gulak L, Zablotska L &Howe G. Post-Chernobyl thyroid cancers in Ukraine. Report 2: risk analysis. Radiation Research 2006 166 375-386. (doi:10.1667/RR3593.1)
6. Jacob P, Bogdanova TI, Buglova E, Chepurniy M, Demidchik Y, Gavrilin Y, Kenigsberg J, Kruk J, Schotola C, Shinkarev S, Tronko MD & Vavilov S. Thyroid cancer among Ukrainians and Belarusians who were children or adolescents at the time of the Chernobyl accident. Journal of Radiological Protection 2006 26 51-67. (doi:10.1088/0952-4746/26/1/003)
7. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA & Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004 23 7436-7440. (doi:10.1038/sj.onc.1207980)
8. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 2007 246 466-470 (discussion 470-461). (doi:10.1097/SLA.0b013e318148563d)
9. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G,Williams D & Sobrinho-Simoes M. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 4267-4271. (doi:10.1210/jc.2003-032224)
10. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA & Nikiforov YE. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters 2004 209 1-6. (doi:10.1016/j.canlet.2003.12.004)
11. Collins BJ, Schneider AB, Prinz RA & Xu X. Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure. Thyroid 2006 16 61-66. (doi:10.1089/thy.2006.16.61)
12. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M & Thomas G. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. Journal of Pathology 2005 205 558-564. (doi:10.1002/path.1736)
13. Santoro M, Melillo RM & Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. European Journal of Endocrinology 2006 155 645-653. (doi:10.1530/eje.1.02289)
14. Kjellman P, Learoyd DL, Messina M, Weber G, Hoog A, Wallin G, Larsson C, Robinson BG & Zedenius J. Expression of the RET protooncogene in papillary thyroid carcinoma and its correlation with clinical outcome. British Journal of Surgery 2001 88 557-563. (doi:10.1046/j.1365-2168.2001.01734.x)
15. Ory C, Ugolin N, Levalois C, Lacroix L, Caillou B, Bidart JM, Schlumberger M, Diallo I, de Vathaire F, Hofman P, Santini J, Malfoy B & Chevillard S. Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors. Endocrine-Related Cancer 2011 18 193-206. (doi:10.1677/ERC-10-0205)
16. Cleland MM, Norris KL, Karbowski M, Wang C, Suen DF, Jiao S, George NM, Luo X, Li Z & Youle RJ. Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death and Differentiation 2011 18 235-247. (doi:10.1038/cdd.2010.89)
17. Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V & Mitsiades N. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. Journal of Clinical Endocrinology and Metabolism 2007 92 4845-4852. (doi:10.1210/jc.2007-0942)
18. Siironen P, Nordling S, Louhimo J, Haapiainen R & Haglund C. Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biology 2005 26 50-56. (doi:10.1159/000084340)
19. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C & Zedenius J. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 2003 13 371-380. (doi:10.1089/105072503321669866)
20. Sofiadis A, Tani E, Foukakis T, Kjellman P, Skoog L, Hoog A, Wallin G, Zedenius J & Larsson C. Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. International Journal of Oncology 2009 35 369-374. (doi:10.3892/ijo-00000348)
21. Viacava P, Bocci G, Tonacchera M, Fanelli G, DeServi M, Agretti P, Berti E, Goletti O, Aretini P, RestaML, Bevilacqua G & Naccarato AG. Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 2007 17 191-197. (doi:10.1089/thy.2006.0175)
22. Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K & Miya A. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World Journal of Surgery 2010 34 3015-3021. (doi:10.1007/s00268-010-0746-3)
23. Chibazakura T, Kamachi K, Ohara M, Tane S, Yoshikawa H &Roberts JM. Cyclin A promotes S-phase entry via interaction with the replication licensing factor Mcm7. Molecular and Cellular Biology 2011 31 248-255. (doi:10.1128/MCB.00630-10)
24. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML &Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 2007 51 491-498. (doi:10.1111/j.1365- 2559.2007.02798.x)
25. Ito Y, Yoshida H, Nakano K, Takamura Y, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K & Miyauchi A. Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation. Pathology, Research and Practice 2002 198 397-402. (doi:10.1078/0344-0338- 00272)
26. Nar A, Ozen O, Tutuncu NB & Demirhan B. Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma. Medical Oncology 2011 29 294-300. (doi:10.1007/s12032-010-9800-0)
27. Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, Palmieri EA, Conzo G, Papotti M & Palombini L. Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. Cancer Cytopathology 2009 117 522-529. (doi:10.1002/cncy.20050)
28. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, Namba H, Ito M, Abrosimov A, Lushnikov E, Sekine I &Yamashita S. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 2005 47 248-256. (doi:10.1111/j.1365-2559.2005.02218.x)
29. Sofiadis A, Dinets A, Orre LM, Branca RM, Juhlin CC, Foukakis T, Wallin G, Hoog A, Hulchiy M, Zedenius J, Larsson C & Lehtio J. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2C-binding protein S100A6 in papillary thyroid carcinoma. Thyroid 2010 20 1067-1076. (doi:10.1089/thy. 2009.0400)
30. Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR & Tallini G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Laboratory Investigation 2004 84 1557-1570. (doi:10.1038/labinvest.3700198)
31. Cyniak-Magierska A, Wojciechowska-Durczynska K, Krawczyk-Rusiecka K, Zygmunt A & Lewinski A. Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis. Thyroid Research 2011 4 5. (doi:10.1186/1756-6614-4-5)
32. Katz RL, Caraway NP, Gu J, Jiang F, Pasco-Miller LA, Glassman AB, Luthra R, Hayes KJ, Romaguera JE, Cabanillas FF & Medeiros LJ. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. American Journal of Clinical Pathology 2000 114 248-257. (doi:10.1309/69EJ-RFM5-E976- BUTP)
33. Achille M, Boukheris H, Caillou B, Talbot M, de Vathaire F, Sabatier L, Desmaze C, Schlumberger M & Soria JC. Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers. American Journal of Clinical Oncology 2009 32 1-8. (doi:10.1097/COC.0b013e3181783336)
34. Lee SH, Lee JK, Jin SM, Lee KC, Sohn JH, Chae SW & Kim DH. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma. Otolaryngology - Head and Neck Surgery 2010 142 332-337. (doi:10.1016/j.otohns.2009.10.050)
35. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB & Nikiforov YE. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009 146 1215-1223. (doi:10.1016/j.surg.2009.09.011)
36. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A & Santeusanio F. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 2414-2420. (doi:10.1210/jc.2003- 031425)
37. Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG & Fugazzola L. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clinical Endocrinology 2010 72 702-708. (doi:10.1111/j.1365- 2265.2009.03699.x)
38. Sargent R, LiVolsi V, Murphy J, Mantha G & Hunt JL. BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocrine Pathology 2006 17 235-241. (doi:10.1385/EP:17:3:235)
39. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM & Clayman GL. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clinical Cancer Research 2009 15 485-491. (doi:10.1158/1078-0432.CCR-08-0933)
40. O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R & Sywak MS. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010 148 1139-1145 (discussion 1145-1146). (doi:10.1016/j.surg.2010.09.005)
41. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T & Nakayama I. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998 8 197-202. (doi:10.1089/thy.1998.8.197)
42. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, Hong SJ, Gong G & Shong YK. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clinical Endocrinology 2009 71 581-586. (doi:10.1111/j.1365-2265.2009.03537.x)
43. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G & Vitale M. The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2012 97 517-524. (doi:10.1210/jc.2011- 0618)
44. Nakazawa T, Kondo T, Kobayashi Y, Takamura N, Murata S, Kameyama K, Muramatsu A, Ito K, Kobayashi M & Katoh R. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer 2005 104 943-951. (doi:10.1002/cncr.21270)
45. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, TronkoMD,Nagayasu T, Shibata Y & Yamashita S. Lowfrequency of BRAFT1796Amutations inchildhood thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 4280-4284. (doi:10.1210/jc.2004-0172)
46. Maenhaut C, Detours V, Dom G, Handkiewicz-Junak D, Oczko-Wojciechowska M & Jarzab B. Gene expression profiles for radiation-induced thyroid cancer. Clinical Oncology 2011 23 282-288. (doi:10.1016/j.clon.2011.01.509)
47. Hess J, Thomas G, Braselmann H, Bauer V, Bogdanova T, Wienberg J, Zitzelsberger H & Unger K. Gain of chromosome band 7q11 in papillary thyroid carcinomas of young patients is associated with exposure to low-dose irradiation. PNAS 2011 108 9595-9600. (doi:10.1073/pnas.1017137108)
48. Okayasu I, Saegusa M, Fujiwara M, Hara Y & Rose NR. Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. Journal of Cancer Research and Clinical Oncology 1995 121 746-752. (doi:10.1007/BF01213321)
49. Preto A, Goncalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P &Sobrinho-Simoes M. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 2009 9 387. (doi:10.1186/1471-2407-9-387)
50. Bassik MC, Scorrano L, Oakes SA, Pozzan T & Korsmeyer SJ. Phosphorylation of BCL-2 regulates ER Ca2C homeostasis and apoptosis. EMBO Journal 2004 23 1207-1216. (doi:10.1038/sj.emboj.7600104)
51. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC & Vigushin DM. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Molecular Cancer 2006 5 7. (doi:10.1186/1476- 4598-5-7)
52. Sumrejkanchanakij P, Eto K & Ikeda MA. Cytoplasmic sequestration of cyclin D1 associated with cell cycle withdrawal of neuroblastoma cells. Biochemical and Biophysical Research Communications 2006 340 302-308. (doi:10.1016/j.bbrc.2005.11.181)
53. Alama A, Barbieri F, Spaziante R, Bruzzo C, Dadati P, Dorcaratto A & Ravetti JL. Significance of cyclin D1 expression in meningiomas: a preliminary study. Journal of Clinical Neuroscience 2007 14 355-358. (doi:10.1016/j.jocn. 2006.04.001)
54. Brzezianska E, Cyniak-Magierska A, Sporny S, Pastuszak-Lewandoska D & Lewinski A. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions. Neuro Endocrinology Letters 2007 28 341-350. (Pubitemid 47577710)
55. MelckA,MasoudiH,GriffithOL,RajputA,WilkinsG,Bugis S, Jones SJ &Wiseman SM. Cell cycle regulators showdiagnostic and prognostic utility for differentiated thyroid cancer. Annals of Surgical Oncology 2007 14 3403-3411. (doi:10.1245/s10434-007-9572-8)
56. Pesutic-Pisac V, Punda A, Gluncic I, Bedekovic V, Pranic-Kragic A & Kunac N. Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croatian Medical Journal 2008 49 643-649. (doi:10.3325/cmj.2008.5.643)